Posted by Michael Wonder on 24 Feb 2020
Teva announces FDA approval of ArmonAir Digihaler (fluticasone propionate) inhalation powder
24 February 2020 - Teva’s digital inhaler portfolio now includes products from three of the most commonly prescribed classes of asthma treatments.
Teva Respiratory, an affiliate of Teva Pharmaceutical Industries announced today that the U.S. FDA has approved ArmonAir Digihaler (fluticasone propionate) inhalation powder, an inhaled corticosteroid delivered via Teva’s Digihaler device, which contains built-in sensors and connects to a companion mobile application that provides information on inhaler use to people with asthma.
ArmonAir Digihaler is indicated for the maintenance treatment of asthma in patients 12 years and older. ArmonAir Digihaler is not indicated for the relief of acute bronchospasm.
